ADC Therapeutics Income Statement (2019-2026) | ADCT

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter) 19.28M14.49M18.05M17.03M18.02M5.00M18.84M15.75M20.03M
Cost of Revenue (Quarter) 14.46M13.73M11.39M10.70M10.67M10.55M10.15M10.69M12.71M
Gross Profit (Quarter) 4.83M0.76M6.66M6.33M7.34M-5.55M8.69M5.06M7.33M
Operating items
Research & Development (Quarter) 31.34M27.08M25.73M24.30M32.50M28.93M30.09M26.80M19.88M
Selling, General & Administrative (Quarter) 12.00M9.62M12.03M10.24M10.00M9.96M8.82M8.33M9.90M
Restructuring Costs (Quarter) 13.09M0.38M
Other Operating Expenses (Quarter) 15.59M13.94M13.90M11.92M11.52M12.61M10.98M11.89M16.32M
Operating Expenses (Quarter) 58.93M50.64M51.67M46.45M54.03M51.50M62.99M47.40M46.10M
Operating Income (Quarter) -39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M
EBIT (Quarter) -39.65M-36.15M-33.61M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M
Non-operating items
Interest & Investment Income (Quarter) 2.37M2.70M2.95M3.25M3.44M2.05M1.93M2.47M1.99M
Other Non Operating Income (Quarter) -5.07M0.86M-2.60M2.75M1.62M0.20M-0.18M0.93M2.63M
Non Operating Income (Quarter) -13.00M0.86M-12.14M2.75M1.62M0.20M-0.18M0.93M-7.72M
Net income details
EBT (Quarter) -52.65M-45.40M-45.80M-35.71M-43.62M-38.44M-55.39M-40.97M-32.97M
Tax Provisions (Quarter) -4.50M-0.09M0.20M0.23M0.09M0.17M1.25M
Profit After Tax (Quarter) 0.27M-59.37M-48.92M-45.32M-85.03M-45.92M-35.95M-43.71M-32.27M-38.60M-56.65M-40.97M-6.41M-32.97M
Equity Income (Quarter) -0.77M-1.41M-2.43M-0.69M-0.60M-0.26M
Income from Continuing Operations (Quarter) -48.15M-45.31M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Consolidated Net Income (Quarter) -48.15M-45.31M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Income towards Parent Company (Quarter) -48.15M-45.31M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Net Income towards Common Stockholders (Quarter) -48.15M-45.31M-46.00M-35.95M-43.71M-38.60M-56.65M-40.97M-32.97M
Additional items
EPS (Basic) (Quarter) -0.60-0.57-0.56-0.38-0.42-0.36-0.50-0.30-0.21
EPS (Weighted Average and Diluted) (Quarter) -0.60-0.57-0.56-0.38-0.42-0.36-0.50-0.30-0.21
Shares Outstanding (Weighted Average) (Quarter) 53.34M65.41M6.45M78.15M80.81M81.47M82.26M81.71M82.55M89.12M94.39M97.16M107.20M113.74M136.45M127.07M154.14M
Shares Outstanding (Diluted Average) (Quarter) 81.14M81.52M82.55M89.12M104.82M107.20M113.74M136.45M154.14M
EBITDA (Quarter) -59.53M-39.65M-36.15M-46.71M-29.04M-35.56M-28.46M-44.15M-30.97M-25.25M
Interest Expenses (Quarter) 10.31M12.82M12.50M12.68M13.12M12.23M13.00M13.39M12.35M
Tax Rate (Quarter) 8.55%0.19%-0.44%-0.66%-0.21%-0.43%-2.26%